Harbour BioMed Announces Submission of IND Application for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease
Hand-out
Press Releases
November 8, 2024

Harbour BioMed Announces Submission of IND Application for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Nov. 8, 2024 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of

bradford

The Bradford Era

Local & Social